These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24524902)

  • 1. Fisetin antagonizes cell fusion, cytoskeletal organization and bone resorption in RANKL-differentiated murine macrophages.
    Kim YH; Kim JL; Lee EJ; Park SH; Han SY; Kang SA; Kang YH
    J Nutr Biochem; 2014 Mar; 25(3):295-303. PubMed ID: 24524902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
    Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH
    Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
    Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y
    Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fisetin inhibits osteoclastogenesis through prevention of RANKL-induced ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes.
    Sakai E; Shimada-Sugawara M; Yamaguchi Y; Sakamoto H; Fumimoto R; Fukuma Y; Nishishita K; Okamoto K; Tsukuba T
    J Pharmacol Sci; 2013; 121(4):288-98. PubMed ID: 23538677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
    Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulators of osteoclast differentiation and cell-cell fusion.
    Miyamoto T
    Keio J Med; 2011; 60(4):101-5. PubMed ID: 22200633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiosteoclastogenic activity of silicate-based materials antagonizing receptor activator for nuclear factor kappaB ligand-induced osteoclast differentiation of murine marcophages.
    Hung CJ; Kao CT; Chen YJ; Shie MY; Huang TH
    J Endod; 2013 Dec; 39(12):1557-61. PubMed ID: 24238446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
    Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
    J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice.
    Lee EJ; Kim JL; Kim YH; Kang MK; Gong JH; Kang YH
    Phytomedicine; 2014 Sep; 21(10):1208-15. PubMed ID: 24932975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
    Park EK; Kim MS; Lee SH; Kim KH; Park JY; Kim TH; Lee IS; Woo JT; Jung JC; Shin HI; Choi JY; Kim SY
    Biochem Biophys Res Commun; 2004 Dec; 325(4):1472-80. PubMed ID: 15555594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2.
    Kwon JO; Jin WJ; Kim B; Kim HH; Lee ZH
    Eur J Pharmacol; 2015 Dec; 768():189-98. PubMed ID: 26528796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.